Masimo Corporation Stock Fair Value Calculation – Masimo Co. Expected to Post Record Q3 2023 Earnings of $1.24 Per Share
April 1, 2023
Trending News ☀️
Masimo Co. (NASDAQ:MASI), a world leader in cutting-edge noninvasive medical technology, is expected to post record earnings of $1.24 per share for the third quarter of 2023, according to a recent prediction by Zacks Research. MASIMO CORPORATION ($NASDAQ:MASI) is a publicly traded company on the NASDAQ with a long history of developing innovative and effective medical technology. The company has a variety of products, including pulse oximeters and rainbow SET technology, designed to improve patient outcomes and reduce costs for healthcare providers. MASIMO CORPORATION has also led the way in the development of remote patient monitoring technology, which will become increasingly important as healthcare systems around the world become more efficient and integrated.
In addition, the company holds a number of strategic partnerships with some of the biggest names in the healthcare industry. It is a testament to the company’s ability to innovate and grow in an ever-changing healthcare landscape. With continued support from its partners and customers, MASIMO CORPORATION should be well-positioned to take advantage of new opportunities while continuing to create value for its shareholders.
Market Price
On Monday, MASIMO CORPORATION opened at a stock price of $173.7 and closed at $173.6, up from its previous closing price of $172.9. This surge in stock value comes in anticipation of the company’s scheduled release of its third quarter 2023 earnings, which are expected to be a record high of $1.24 per share. Analysts anticipate that the company will continue to post strong performance in the upcoming quarter. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Masimo Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.04k | 143.5 | 6.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Masimo Corporation. More…
| Operations | Investing | Financing |
| 29.4 | -1.06k | 520.4 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.21k | 1.87k | 25.45 |
Key Ratios Snapshot
Some of the financial key ratios for Masimo Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 29.5% | -1.7% | 10.8% |
| FCF Margin | ROE | ROA |
| -1.3% | 10.6% | 4.3% |
Analysis – Masimo Corporation Stock Fair Value Calculation
At GoodWhale, we conducted an analysis of MASIMO CORPORATION‘s financials and determined that the intrinsic value of MASIMO CORPORATION’s share is around $346.2. This value was calculated by our proprietary Valuation Line, which enables us to assess the true value of a company. Currently, MASIMO CORPORATION’s stock is traded at $173.6, meaning it is undervalued by 49.9%. This presents an opportunity for investors to purchase MASIMO CORPORATION’s stock at a discount and benefit from potential upside. More…
Peers
In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.
– Elekta AB ($OTCPK:EKTAY)
Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.
– Essilorluxottica ($LTS:0OMK)
EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.
– Compumedics Ltd ($ASX:CMP)
Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.
Summary
Investors interested in the company should consider key fundamentals such as the company’s financial stability, products/services, competitive advantages, and industry trends. Its competitive advantages lie in its technology, research, and development capabilities, and its ability to respond to the needs of its global customers. Additionally, the company is well placed in the medical technology industry, which is poised to benefit from the rise of aging populations and health care reform initiatives.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
